Is it prime time for the “next-gen” biopharma acquirers? The headlines have flourished since April. Genmab and Ono Pharmaceutical made their first acquisitions. Vertex inked its largest M&A deal since its founding. Incyte went back to the acquisition well after a brief period on the sidelines. Biogen quickly returned to shopping mode after having just digested its first acquisition in four years. Asahi Kasei forged a biotech consummation for the first time since 2019. The past three months were the best stretch of the previous five quarters in terms of M&A deal value and count by this so-called “next-generation” group, according to investment bank William Blair’s latest quarterly industry analysis.
Read the full article: Are ‘Next-Gen’ Biotech Acquirers Experiencing Their Moment? //
Source: https://endpts.com/next-gen-biotech-acquirers-find-ma-momentum-in-q2/